Vereülekande alternatiivmeetodite majanduslik tasuvus
Hematoloogia
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (opens new window)
Allikas: Blood Transfus 2020;18(2):106-16.
Indekseeritud: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (opens new window)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (opens new window)
Allikas: Support Care Cancer 2013;21(2):485-93.
Indekseeritud: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (opens new window)
Restrictive blood transfusion practices are associated with improved patient outcomes. (opens new window)
Allikas: Transfusion 2014;54(10 Pt 2):2753-9.
Indekseeritud: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (opens new window)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (opens new window)
Allikas: Clin Ther 2010;32(14):2478-93.
Indekseeritud: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (opens new window)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (opens new window)
Allikas: J Pediatr Surg 2008;43(12):2235-8.
Indekseeritud: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (opens new window)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (opens new window)
Allikas: Blood Adv. 2022;6(3):785-92.
Indekseeritud: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (opens new window)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (opens new window)
Allikas: Transfusion 2017;57(9):2189-96.
Indekseeritud: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (opens new window)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (opens new window)
Allikas: Biol Blood Marrow Transplant 2012;18(5):813-7.
Indekseeritud: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (opens new window)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (opens new window)
Allikas: Transfusion 2019;59(11):3386-95.
Indekseeritud: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (opens new window)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (opens new window)
Allikas: Transfusion 2015;55(12):2807-15.
Indekseeritud: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (opens new window)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)
Allikas: Cancer 2013;119(1):107-14.
Indekseeritud: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (opens new window)
Allikas: Cost Eff Resour Alloc 2013;11(1):16.
Indekseeritud: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (opens new window)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opens new window)
Allikas: Support Care Cancer 2012;20(1):159-65.
Indekseeritud: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opens new window)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (opens new window)
Allikas: J Med Econ 2013;16(2):318-26.
Indekseeritud: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (opens new window)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (opens new window)
Allikas: Hematology 2018;23(7):417-22.
Indekseeritud: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (opens new window)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (opens new window)
Allikas: J Med Econ 2013;16(5):633-8.
Indekseeritud: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (opens new window)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (opens new window)
Allikas: Transfusion 2010;50(2):487-92.
Indekseeritud: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (opens new window)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (opens new window)
Allikas: Am J Hematol 2010;85(10):795-7.
Indekseeritud: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (opens new window)
Increased hospital costs associated with red blood cell transfusion. (opens new window)
Allikas: Transfusion 2015;55(5):1082-9.
Indekseeritud: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (opens new window)